Matches in SemOpenAlex for { <https://semopenalex.org/work/W4239947316> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W4239947316 endingPage "1279" @default.
- W4239947316 startingPage "1279" @default.
- W4239947316 abstract "Parathyroid carcinoma (PC) is an uncommon finding, accounting for only 1-2% of patients with primary hyperparathyroidism (HPT), but a relatively higher incidence has been reported in Italy and Japan. The etiology of the tumour remains unclear, but molecular analysis studies have hypothesised the involvement of mutations of several genes in the pathogenesis of PC, including the oncogene cyclin D1 or PRAD1 located at the chromosome 13, the retinoblastoma and the p53 tumour suppressor gene. The clinical presentation of patients with PC is mainly related to the increased secretion of PTH rather than to the tumour burden. The pre-operative diagnosis of malignancy is very difficult to obtain, and, thus, intra-operative recognition of PC is mandatory. However, reliable signs of malignancy are rarely detectable. Probably, only vascular invasion, that correlates with tumour recurrence and metastases, should be considered useful in confirming malignancy, although both Ki-67 and Cyclin D1 have been recently used to aid in the definitive diagnosis. The en bloc resection of the tumour, together with ipsilateral thyroid lobe and adjacent structures, only if involved, avoiding any capsular rupture of the mass, represents the gold standard of surgical treatment of patients. Although the PC has traditionally been considered as a radioresistant tumour, there are some retrospective data holding a possible benefit from post-operative irradiation. No cytotoxic regimen with proven efficacy is currently available for patients with PC, but since hypercalcemia is ultimately the most frequent cause of death, several studies have suggested the usefulness of bisphosphonates (i.e., clodronate, pamidronate and zoledronate), calcitonin, and calcimimetic agents (i.e., cinacalcet) in patients with PC and severe hypercalcemia. In conclusion, PC is a rare malignancy and the NCDB survey reports an overall five- and ten-year survival rate of 85% and 49%, respectively. However, it is very difficult to predict the clinical behaviour of patients with PC and probably the ultimate prognosis depends on successful resection of the tumour at the initial surgery." @default.
- W4239947316 created "2022-05-12" @default.
- W4239947316 creator A5019110228 @default.
- W4239947316 date "1987-11-14" @default.
- W4239947316 modified "2023-09-26" @default.
- W4239947316 title "RAWP revisited" @default.
- W4239947316 cites W2416438162 @default.
- W4239947316 cites W2801568285 @default.
- W4239947316 doi "https://doi.org/10.1136/bmj.295.6608.1279-b" @default.
- W4239947316 hasPublicationYear "1987" @default.
- W4239947316 type Work @default.
- W4239947316 citedByCount "0" @default.
- W4239947316 crossrefType "journal-article" @default.
- W4239947316 hasAuthorship W4239947316A5019110228 @default.
- W4239947316 hasConcept C120665830 @default.
- W4239947316 hasConcept C121332964 @default.
- W4239947316 hasConcept C121608353 @default.
- W4239947316 hasConcept C126322002 @default.
- W4239947316 hasConcept C137627325 @default.
- W4239947316 hasConcept C142724271 @default.
- W4239947316 hasConcept C143998085 @default.
- W4239947316 hasConcept C199835354 @default.
- W4239947316 hasConcept C2779053571 @default.
- W4239947316 hasConcept C2779399171 @default.
- W4239947316 hasConcept C29537977 @default.
- W4239947316 hasConcept C502942594 @default.
- W4239947316 hasConcept C61511704 @default.
- W4239947316 hasConcept C71924100 @default.
- W4239947316 hasConceptScore W4239947316C120665830 @default.
- W4239947316 hasConceptScore W4239947316C121332964 @default.
- W4239947316 hasConceptScore W4239947316C121608353 @default.
- W4239947316 hasConceptScore W4239947316C126322002 @default.
- W4239947316 hasConceptScore W4239947316C137627325 @default.
- W4239947316 hasConceptScore W4239947316C142724271 @default.
- W4239947316 hasConceptScore W4239947316C143998085 @default.
- W4239947316 hasConceptScore W4239947316C199835354 @default.
- W4239947316 hasConceptScore W4239947316C2779053571 @default.
- W4239947316 hasConceptScore W4239947316C2779399171 @default.
- W4239947316 hasConceptScore W4239947316C29537977 @default.
- W4239947316 hasConceptScore W4239947316C502942594 @default.
- W4239947316 hasConceptScore W4239947316C61511704 @default.
- W4239947316 hasConceptScore W4239947316C71924100 @default.
- W4239947316 hasIssue "6608" @default.
- W4239947316 hasLocation W42399473161 @default.
- W4239947316 hasOpenAccess W4239947316 @default.
- W4239947316 hasPrimaryLocation W42399473161 @default.
- W4239947316 hasRelatedWork W1567322 @default.
- W4239947316 hasRelatedWork W1999568792 @default.
- W4239947316 hasRelatedWork W2038743689 @default.
- W4239947316 hasRelatedWork W2065690661 @default.
- W4239947316 hasRelatedWork W2403761501 @default.
- W4239947316 hasRelatedWork W2409473452 @default.
- W4239947316 hasRelatedWork W2411146340 @default.
- W4239947316 hasRelatedWork W2461652061 @default.
- W4239947316 hasRelatedWork W2735380213 @default.
- W4239947316 hasRelatedWork W2764038087 @default.
- W4239947316 hasVolume "295" @default.
- W4239947316 isParatext "false" @default.
- W4239947316 isRetracted "false" @default.
- W4239947316 workType "article" @default.